| Literature DB >> 35975050 |
Yokari Godínez-Loyola1, Jesús Gracia-Mora1, Iván D Rojas-Montoya1, Luis Felipe Hernández-Ayala1, Miguel Reina1, Luis Antonio Ortiz-Frade2, Luisa Alondra Rascón-Valenzuela3, Ramón Enrique Robles-Zepeda3, Virginia Gómez-Vidales4, María Josefa Bernad-Bernad1, Lena Ruiz-Azuara1.
Abstract
Seven new Casiopeinas® were synthesized and properly characterized. These novel compounds have a general formula [Cu(N-N)(Indo)]NO3, where Indo is deprotonated indomethacin and N-N is either bipyridine or phenanthroline with some methyl-substituted derivatives, belonging to the third generation of Casiopeinas®. Spectroscopic characterization suggests a square-based pyramid geometry and voltammetry experiments indicate that the redox potential is strongly dependent on the N-N ligand. All the presented compounds show high cytotoxic efficiency, and most of them exhibit higher efficacy compared to the well-known cisplatin drug and acetylacetonate analogs of the first generation. Computational calculations show that antiproliferative behavior can be directly related to the volume of the molecules. Besides, a chitosan (CS)-polyacrylamide (PNIPAAm) nanogel was synthesized and characterized to examine the encapsulation and release properties of the [Cu(4,7-dimethyl-1,10-phenanthroline)(Indo)]NO3 compound. The results show good encapsulation performance in acidic conditions and a higher kinetic drug release in acidic media than at neutral pH. This result can be described by the Peppas-Sahlin model and indicates a release mechanism predominantly by Fick diffusion. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 35975050 PMCID: PMC9347768 DOI: 10.1039/d2ra03346a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Scheme 1The seven heteroleptic complexes of CuII under study.
Fig. 1Cyclic voltammogram of 0.001 mol L−1 [Cu(4,4′-dimethyl-2,2′-bipyridine)(Indo)]NO3, 0.1 mol L−1 TBAPF6 in DMSO, v = 0.1 V s−1.
Redox potential (E1/2)
| Compounds |
|
|---|---|
| [Cu(1,10-phenanthroline)( | −0.66 |
| [Cu(4,7-dimethyl-1,10-phenanthroline)( | −0.83 |
| [Cu(5,6-dimethyl-1,10-phenanthroline)( | −0.63 |
| [Cu(3,4,7,8-tetramethyl-1,10-phenanthroline)( | −0.65 |
| [Cu(2,2′-bipyridine)( | −0.65 |
| [Cu(4,4′-dimethyl-2,2′-bipyridine)( | −0.72 |
| [Cu(5,5′-dimethyl-2,2′-bipyridine)( | −0.76 |
IC50 results against HeLa cervical cancer cells
| Compounds | IC50 (μmol L−1) | Log (IC50) | IC50 acac |
|---|---|---|---|
| Cisplatin | 12.5 ± 0.70 | 1.10 | — |
| [Cu(1,10-phenanthroline)( | 2.30 ± 0.02 | 0.36 | 10.7 ± 0.9 |
| [Cu(4,7-dimethyl-1,10-phenanthroline)( | 0.72 ± 0.10 | −0.14 | 1.4 ± 0.1 |
| [Cu(5,6-dimethyl-1,10-phenanthroline)( | 0.67 ± 0.02 | −0.17 | 3.4 ± 0.5 |
| [Cu(3,4,7,8-tetramethyl-1,10-phenanthroline)( | 1.00 ± 0.03 | 0.00 | 1.9 ± 0.2 |
| [Cu(2,2′-bipyridine)( | 25.2 ± 1.07 | 1.40 | 42.0 ± 3.1 |
| [Cu(4,4′-dimethyl-2,2′-bipyridine)( | 7.87 ± 0.40 | 0.90 | 18.2 ± 2.7 |
| [Cu(5,5′-dimethyl-2,2′-bipyridine)( | 2.87 ± 1.02 | 0.46 | N.R. |
| Cu(NO3)2 | >100 | >2 | — |
Ref. 29, N.R.: not reported.
Fig. 2Antiproliferative activity and molar volume relations.
Scheme 2Scheme of CS–NIPAAm synthesis.
Nanogel characterization indexes
| pH |
| Hydrodynamic diameter (nm) |
| PDI |
|---|---|---|---|---|
| 5.0 | 25 | 690.27 ± 7.10 | 22.97 ± 0.55 | 0.530 |
| 37 | 654.13 ± 32.07 | 23.50 ± 0.35 | 0.512 | |
| 7.4 | 25 | 108.92 ± 12.85 | −6.81 ± 0.45 | 0.573 |
| 37 | 100.89 ± 8.33 | −5.81 ± 1.90 | 0.540 |
Fig. 3Micrographs for the nanogel at pH: 5.0 (left) and 7.4 (right).
Fig. 4Percentage of in vitro cumulative [Cu(4,7-dimethyl-1,10-phenanthroline)(Indo)]NO3 released as a time function.
Kinetic parameters of the Peppas–Sahlin model for drug release
| Parameter | pH = 5.0 | pH = 7.4 |
|---|---|---|
|
| 82.402 ± 0.942 | 40.907 ± 1.815 |
|
| −18.350 ± 0.382 | −6.397 ± 0.408 |
|
| 0.522 ± 0.010 | 0.665 ± 0.024 |